Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.87USD
9 Dec 2016
Change (% chg)

$0.06 (+7.35%)
Prev Close
$0.81
Open
$0.81
Day's High
$0.87
Day's Low
$0.81
Volume
150,703
Avg. Vol
80,148
52-wk High
$2.75
52-wk Low
$0.73

SYN.A

Chart for SYN.A

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $101.52
Shares Outstanding(Mil.): 116.65
Dividend: --
Yield (%): --

Financials

  SYN.A Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -0.39 -- --
ROI: -335.98 -0.36 15.24
ROE: -335.28 -0.94 16.58

BRIEF-Sabby Management reports 5.14 pct passive stake in Synthetic Biologics

* Sabby Management LLC reports 5.14 percent passive stake in Synthetic Biologics Inc as of November 15 - sec filing Source text : http://bit.ly/2f8su9r Further company coverage:

Nov 17 2016

BRIEF-Synthetic Biologics announces pricing of public offering of common stock

* Pricing of offering of 25 million shares of its common stock and warrants to purchase 50 million shares of common stock at $1.00/share

Nov 15 2016

BRIEF-Synthetic Biologics says commences offering of stock and warrants

* Synthetic Biologics - using net proceeds from offering primarily to provide necessary funding for continued clinical development of SYN-010

Nov 14 2016

BRIEF-Synthetic Biologics posts quarterly loss of 9 cents/share

* Synthetic biologics reports third quarter 2016 operational highlights and financial results Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Synthetic Biologics awarded research contract from Centers for Disease Control and Prevention (CDC)

* Synthetic Biologics awarded research contract from Centers For Disease Control And Prevention (CDC) for microbiome assessment and intervention to address antibiotic resistance

Oct 06 2016

BRIEF-Synthetic Biologics announces completion of enrollment for Phase 2b

* Announces completion of enrollment for Phase 2b Proof-Of-Concept clinical trial for SYN-004 (ribaxamase)

Sep 20 2016

BRIEF-Synthetic Biologics and FBR Capital Markets enter into a sales agreement

* On August 5, 2016, co and FBR Capital Markets & Co entered into an at market issuance sales agreement - SEC filing

Aug 05 2016

BRIEF-Synthetic Biologics reports Q2 2016 operational highlights & financial results

* Synthetic Biologics reports second quarter 2016 operational highlights and financial results

Aug 03 2016

BRIEF-Synthetic Biologics announces completion of end of phase 2 meeting with FDA for SYN-010

* Announces completion of end of phase 2 meeting with FDA for SYN-010, intended for the treatment of irritable bowel syndrome with constipation (IBS-C) Source text for Eikon: Further company coverage:

Aug 02 2016

BRIEF-Synthetic Biologics gets European, U.S. composition of matter patents for Ribaxamase

* Synthetic Biologics announces granting of European and U.S. composition of matter patents for Ribaxamase Source text for Eikon: Further company coverage:

Jul 12 2016

Earnings vs. Estimates